Showing 2731-2740 of 7016 results for "".
Engaging Neuroplasticity in Depression with Cognitive-Emotional Training
https://reachmd.com/programs/medical-industry-feature/neuroplasticity-depression-cognitive-emotional-training/29736/Since the unhelpful thinking patterns of depression involve getting stuck on sad or negative thoughts, researchers have focused on improving the cognitive control of emotional information processing specifically.1 To learn more about cognitive-emotional training as a potential digital therapeutic,Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
https://reachmd.com/programs/cme/efficacy-and-safety-outcomes-for-adjuvant-immunotherapy-driving-guideline-recommendations-for-stage-iiiiv-melanoma/36325/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Ongoing Clinical Trials in AML With Menin Inhibitors
https://reachmd.com/programs/cme/ongoing-clinical-trials-in-aml-with-menin-inhibitors/36185/Explore advances in AML that integrate risk stratification, molecular profiling, and menin-targeted therapies to optimize care and improve outcomes.New Pathways in the Treatment of DMD
https://reachmd.com/programs/cme/new-pathways-in-the-treatment-of-dmd/48924/The Duchenne muscular dystrophy (DMD) treatment landscape continues to evolve, with promising therapies emerging from new insights into disease biology. This activity explores the role of aberrant histone deacetylase (HDAC) activity in DMD pathophysiology, including its impact on inflammation, musclData Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
https://reachmd.com/programs/cme/data-driving-preferred-guideline-recommendations-in-first-line-therapy-for-metastatic-melanoma/36327/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
https://reachmd.com/programs/cme/implementing-guideline-concordant-care-for-a-patient-with-newly-diagnosed-stage-iii-melanoma/36326/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Pivotal Data in Anti-PD-1 Strategies for HER2-Negative Upper GI Cancers
https://reachmd.com/programs/cme/pivotal-data-in-anti-pd-1-strategies-for-her2-negative-upper-gi-cancers/37690/Partnering with Patients: Improving First-Line Treatment Selection in Upper GI Cancers Through Shared Decision-MakingRedefining The Cash-Pay Model in Modern Optometric Practice
https://reachmd.com/programs/empower/redefining-the-cash-pay-model-in-modern-optometric-practice/48689/Innovative strategies for independent practice growth.Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
https://reachmd.com/programs/cme/insights-from-global-key-opinion-leaders-on-regional-regulatory-and-guideline-nuances-to-optimize-melanoma-management/36331/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.MS Treatment Decisions: When to Discontinue Disease-Modifying Therapies
https://reachmd.com/programs/neurofrontiers/ms-treatment-decisions-when-to-discontinue-disease-modifying-therapies/17929/Given risk factors involving disease-modifying therapies for MS, stable patients may want to discontinue them. Here’s how to approach this decision.